Video

Dr. Jones on the Importance of Immune Checkpoint Inhibitors in CRC

Jeremy C. Jones, MD, discusses key lessons learned from the phase 3 KEYNOTE-177 trial.

Jeremy C. Jones, MD, hematologist/oncologist, Mayo Clinic, discusses key lessons learned from the phase 3 KEYNOTE-177 trial (NCT02563002), which examined the use of the checkpoint inhibitor pembrolizumab (Keytruda) in patients with microsatellite instability–high or mismatch repair deficient stage IV colorectal cancer.

Approximately 40% of the patients who were enrolled to the phase 3 trial had not received treatment with immune checkpoint inhibitors at any time point during their disease course, which is not best practice, according to Jones. It has been shown that even patients with a high disease burden or marginal performance status can achieve responses to immune checkpoint inhibitors and experience improved outcomes, Jones notes. As such, it is important to utilize immune checkpoint inhibitors in the treatment of this patient population, preferably in the first-line setting, Jones concludes.

Related Videos
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD